CA2538305C - Apheresis device - Google Patents

Apheresis device Download PDF

Info

Publication number
CA2538305C
CA2538305C CA2538305A CA2538305A CA2538305C CA 2538305 C CA2538305 C CA 2538305C CA 2538305 A CA2538305 A CA 2538305A CA 2538305 A CA2538305 A CA 2538305A CA 2538305 C CA2538305 C CA 2538305C
Authority
CA
Canada
Prior art keywords
app
column
binding
apheresis
nucleic acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2538305A
Other languages
English (en)
French (fr)
Other versions
CA2538305A1 (en
Inventor
Frank Mattner
Walter Schmidt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Affiris Forschungs und Entwicklungs GmbH
Original Assignee
Affiris Forschungs und Entwicklungs GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34280361&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2538305(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Affiris Forschungs und Entwicklungs GmbH filed Critical Affiris Forschungs und Entwicklungs GmbH
Publication of CA2538305A1 publication Critical patent/CA2538305A1/en
Application granted granted Critical
Publication of CA2538305C publication Critical patent/CA2538305C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
    • A61M1/3486—Biological, chemical treatment, e.g. chemical precipitation; treatment by absorbents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Vascular Medicine (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Anesthesiology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Pathology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • External Artificial Organs (AREA)
CA2538305A 2003-09-12 2004-09-13 Apheresis device Expired - Fee Related CA2538305C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ATA1444/2003 2003-09-12
AT0144403A AT413336B (de) 2003-09-12 2003-09-12 Apherese-vorrichtung
PCT/AT2004/000311 WO2005025651A1 (de) 2003-09-12 2004-09-13 Apherese-vorrichtung

Publications (2)

Publication Number Publication Date
CA2538305A1 CA2538305A1 (en) 2005-03-24
CA2538305C true CA2538305C (en) 2011-05-24

Family

ID=34280361

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2538305A Expired - Fee Related CA2538305C (en) 2003-09-12 2004-09-13 Apheresis device

Country Status (15)

Country Link
US (2) US7935252B2 (cg-RX-API-DMAC7.html)
EP (1) EP1663347B1 (cg-RX-API-DMAC7.html)
JP (1) JP4509113B2 (cg-RX-API-DMAC7.html)
CN (1) CN100556472C (cg-RX-API-DMAC7.html)
AT (2) AT413336B (cg-RX-API-DMAC7.html)
AU (1) AU2004271651B2 (cg-RX-API-DMAC7.html)
CA (1) CA2538305C (cg-RX-API-DMAC7.html)
CY (1) CY1107911T1 (cg-RX-API-DMAC7.html)
DE (1) DE502004005851D1 (cg-RX-API-DMAC7.html)
DK (1) DK1663347T3 (cg-RX-API-DMAC7.html)
ES (1) ES2298789T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20080090T3 (cg-RX-API-DMAC7.html)
PL (1) PL1663347T3 (cg-RX-API-DMAC7.html)
PT (1) PT1663347E (cg-RX-API-DMAC7.html)
WO (1) WO2005025651A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003303198A1 (en) 2002-12-19 2004-07-14 New York University Method for treating amyloid disease
AT500483B1 (de) * 2004-07-13 2006-01-15 Mattner Frank Dr Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung
AT501621A1 (de) * 2005-03-15 2006-10-15 Mattner Frank Dr Zusammensetzungen zur verwendung bei der vorbeugung und behandlung der alzheimer- erkrankung
ES2332846B1 (es) * 2007-10-26 2010-07-08 Grifols, S.A. Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivos.
JP2011508622A (ja) * 2007-12-21 2011-03-17 ジーイー・ヘルスケア・バイオ−サイエンシズ・アーベー 化学的に活性化された固相支持体材料の滅菌のための方法
EP2320987A1 (en) * 2008-07-29 2011-05-18 Medtronic, Inc. Apheresis of a target molecule from cerebrospinal fluid
US20100158893A1 (en) * 2008-12-19 2010-06-24 Baxter International Inc. Systems and methods for obtaining immunoglobulin from blood
CA2748561C (en) * 2008-12-22 2016-11-01 Kaneka Corporation A.beta. remover, a.beta. removing apparatus and a.beta. removal system
US20110033463A1 (en) * 2009-08-06 2011-02-10 Medtronic, Inc. Apheresis, administration of agent, or combination thereof
EP2497828A1 (en) * 2011-03-07 2012-09-12 Charité - Universitätsmedizin Berlin Use of aptamers in therapy and/or diagnosis of autoimmune diseases
PT2579042E (pt) 2011-10-04 2014-09-09 Affiris Ag Método para detecção de anticorpos específicos para a numa amostra biológica.
US9717841B2 (en) 2012-09-11 2017-08-01 Gary L. McNeil Closed-circuit device and methods for isolation, modification, and re-administration of specific constituents from a biological fluid source
AU2015286606A1 (en) 2014-07-10 2017-01-12 Affiris Ag Substances and methods for the use in prevention and/or treatment in huntington's disease
CN107074925B (zh) 2014-07-10 2021-08-24 阿费里斯股份公司 用于预防和/或治疗亨廷顿氏病的物质和方法
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
GB201904810D0 (en) * 2019-04-05 2019-05-22 Cynapsedx Ltd The treatment of protein aggregation diseases
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57103649A (en) * 1980-12-18 1982-06-28 Asahi Chemical Ind Sterilized gamma-globulin fixing column
EP0236509B1 (en) 1985-09-19 1993-02-10 Toray Industries, Inc. B2-microglobulin-removing column
JPH01171638A (ja) * 1987-12-25 1989-07-06 Kanegafuchi Chem Ind Co Ltd 血清アミロイドａ蛋白用吸着体
DE3880647T2 (de) * 1987-11-20 1993-11-18 Kanegafuchi Chemical Ind Sorbentmittel für Serum-Amyloid-Proteine.
US5216127A (en) * 1987-11-20 1993-06-01 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Adsorbent for serum amyloid protein
US5604102A (en) * 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
JPH06104122A (ja) 1992-09-21 1994-04-15 Matsushita Electric Ind Co Ltd ロータリートランス
AU691297B2 (en) * 1994-05-13 1998-05-14 Miltenyi Biotec Gmbh Sterile and pyrogen-free columns coupled to protein for binding and removal of substances from blood
DE19515554C2 (de) * 1995-04-27 1999-06-17 Braun Melsungen Ag Verwendung eines Mittels und Vorrichtung zur simultanen extrakorporalen Elimination von Tumor-Nekrose-Faktor alpha und bakteriellen Lipopolysacchariden aus Vollblut oder/und Blutplasma
US5868936A (en) * 1996-06-20 1999-02-09 Baxter International Inc. Affinity membrane system and method of using same
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
DE1257584T1 (de) 2000-02-24 2003-05-28 Lilly Co Eli Humanisierte antikörper, die amyloid beta peptid demarkieren
TWI238251B (en) * 2000-07-13 2005-08-21 Anawrhta Biotech Co Ltd In-vitro adsorbing device using immunity
WO2003051374A2 (en) * 2001-12-17 2003-06-26 New York State Office Of Mental Health SEQUESTRATION OF Aβ IN THE PERIPHERY IN THE ABSENCE OF IMMUNOMODULATING AGENT AS A THERAPEUTIC APPROACH FOR THE TREATMENT OR PREVENTION OF BETA-AMYLOID RELATED DISEASES
AU2003303198A1 (en) * 2002-12-19 2004-07-14 New York University Method for treating amyloid disease
AT413945B (de) * 2003-01-14 2006-07-15 Mattner Frank Dr Impfstoff für die alzheimer-krankheit
AT413946B (de) * 2004-07-13 2006-07-15 Mattner Frank Dr Impfstoff gegen die alzheimer-krankheit
AT500835B1 (de) * 2004-09-13 2007-12-15 Affiris Forschungs & Entwicklungs Gmbh Cholinestertransport-protein-mimotop als atherosklerose-medikament

Also Published As

Publication number Publication date
AT413336B (de) 2006-02-15
ES2298789T3 (es) 2008-05-16
ATA14442003A (de) 2005-07-15
AU2004271651A1 (en) 2005-03-24
JP2007504863A (ja) 2007-03-08
HK1096320A1 (zh) 2007-06-01
JP4509113B2 (ja) 2010-07-21
DK1663347T3 (da) 2008-05-19
PL1663347T3 (pl) 2008-06-30
CN100556472C (zh) 2009-11-04
ATE382383T1 (de) 2008-01-15
DE502004005851D1 (de) 2008-02-14
US20070026029A1 (en) 2007-02-01
HRP20080090T3 (hr) 2008-03-31
EP1663347A1 (de) 2006-06-07
EP1663347B1 (de) 2008-01-02
CY1107911T1 (el) 2013-09-04
AU2004271651B2 (en) 2009-08-06
CN1867365A (zh) 2006-11-22
US20110166327A1 (en) 2011-07-07
CA2538305A1 (en) 2005-03-24
WO2005025651A1 (de) 2005-03-24
US7935252B2 (en) 2011-05-03
PT1663347E (pt) 2008-03-28

Similar Documents

Publication Publication Date Title
US20110166327A1 (en) Apheresis device
Sanchez et al. The selective therapeutic apheresis procedures
US11529445B2 (en) Methods and apparatus for kidney dialysis and extracorporeal detoxification
EP2058335B1 (en) Biocompatible three dimensional matrix for the immobilization of biological substances
NZ330102A (en) Immunoadsorbents for extracorporal apheresis in patients suffering from immune disorders
WO2020176683A1 (en) Whole blood treatment device and methods of removing target agents from whole blood
Spina et al. Chemically modified poly (2‐hydroxyethyl methacrylate) cryogel for the adsorption of heparin
Nakamura et al. Adsorption kinetics of high mobility group box 1 protein in a polyacrylonitrile hemofiltration membrane
EP4003451B1 (en) Device for extracorporeal lowering of asymmetric dimethylarginine and monomethyl arginine levels in human blood
Drexler et al. Albumin dialysis molecular adsorbents recirculating system: impact of dialysate albumin concentration on detoxification efficacy
KR101139103B1 (ko) 아페레시스 장치
JPS62192172A (ja) 吸着体
HK1096320B (zh) 分离性输血-设备
WO2005025650A1 (de) Apherese-vorrichtung
JP7255899B2 (ja) 組織または流体から分子を選択的に除去するためのデバイス
RU2098140C1 (ru) Способ проведения экстракорпоральной иммуносорбции
RU2700605C1 (ru) Сорбент для сочетанного удаления из плазмы человека атерогенных липопротеидов и С-реактивного белка
EP4717352A1 (en) A whole-blood compatible matrix for extracorporeal blood treatment
JPH01158970A (ja) 直接血液潅流用免疫グロブリン吸着材および吸着装置
Yamamoto et al. Selective Removal of Anti‐Acetylcholine Receptor Antibodies and IgG In Vitro with an Immunoadsorbent Containing Immobilized Sulfathiazole
JP2000217909A (ja) 吸着材
Müller-Schulte et al. Removal of β2-microglobulin using grafted affinity adsorbents as therapeutic approach for the treatment of hemodialysis patients
AU2015203537B2 (en) Methods and apparatus for kidney dialysis and extracorporeal detoxification
JPH0611335B2 (ja) 吸着体および除去装置
LOTAN et al. THE REMOVAL OF EXCESS LDL-CHOLESTEROL FROM WHOLE BLOOD

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20170913